Correction: Medicinal Cannabis (MedCan 3): a randomised, multicentre, double-blind, placebo-controlled trial to assess THC/CBD (1:20) to relieve symptom burden in patients with cancer-a study protocol for a randomised controlled trial

Taylan Gurgenci^{1

2}, Janet Hardy³, Georgie Huggett³, Karyn Foster³, Anita Pelecanos⁴, Ristan Greer⁵, Jennifer Philip⁶, Alison Haywood⁷, Ruwani Mendis⁶, Patsy Yates⁸, Phillip Good^{3

9

10}

Affiliations

¹ Mater Research Institute, University of Queensland, Brisbane, Australia. t.gurgenci@uq.edu.au.
² Department of Supportive and Palliative Care, Mater Health, Brisbane, Australia. t.gurgenci@uq.edu.au.
³ Mater Research Institute, University of Queensland, Brisbane, Australia.
⁴ QIMR Berghofer Medical Research Institute, Herston, Australia.
⁵ Torus Research, Brisbane, Australia.
⁶ Department of Medicine, Western Health, Melbourne, Australia.
⁷ Grifth University, Nathan, Australia.
⁸ Queensland University of Technology, Brisbane, Australia.
⁹ Department of Palliative Care, St Vincent's Private Hospital Brisbane, Kangaroo Point, Australia.
¹⁰ Department of Supportive and Palliative Care, Mater Health, Brisbane, Australia.

Published Erratum

Taylan Gurgenci et al. Trials. 2024.

. 2024 May 30;25(1):350.

doi: 10.1186/s13063-024-08195-6.

¹ Mater Research Institute, University of Queensland, Brisbane, Australia. t.gurgenci@uq.edu.au.
² Department of Supportive and Palliative Care, Mater Health, Brisbane, Australia. t.gurgenci@uq.edu.au.
³ Mater Research Institute, University of Queensland, Brisbane, Australia.
⁴ QIMR Berghofer Medical Research Institute, Herston, Australia.
⁵ Torus Research, Brisbane, Australia.
⁶ Department of Medicine, Western Health, Melbourne, Australia.
⁷ Grifth University, Nathan, Australia.
⁸ Queensland University of Technology, Brisbane, Australia.
⁹ Department of Palliative Care, St Vincent's Private Hospital Brisbane, Kangaroo Point, Australia.
¹⁰ Department of Supportive and Palliative Care, Mater Health, Brisbane, Australia.

No abstract available

Erratum for

Medicinal Cannabis (MedCan 3): a randomised, multicentre, double-blind, placebo-controlled trial to assess THC/CBD (1:20) to relieve symptom burden in patients with cancer-a study protocol for a randomised controlled trial.
Gurgenci T, Hardy J, Huggett G, Foster K, Pelecanos A, Greer R, Philip J, Haywood A, Mendis R, Yates P, Good P. Gurgenci T, et al. Trials. 2024 May 1;25(1):293. doi: 10.1186/s13063-024-08091-z. Trials. 2024. PMID: 38693590 Free PMC article.

1. Gurgenci, et al. Medicinal Cannabis (MedCan 3): a randomised, multicentre, double-blind, placebo-controlled trial to assess THC/CBD (1:20) to relieve symptom burden in patients with cancer—a study protocol for a randomised controlled trial. Trials. 2024;25:293. doi: 10.1186/s13063-024-08091-z. - DOI - PMC - PubMed